<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101057</url>
  </required_header>
  <id_info>
    <org_study_id>PS-608</org_study_id>
    <nct_id>NCT05101057</nct_id>
  </id_info>
  <brief_title>A Retrospective Study to Examine the Effect of CMF Stimulation on Primary ACDF Patients</brief_title>
  <official_title>A Retrospective Study to Examine the Effect of Adjuvant Combined Magnetic Field Stimulation on Primary Anterior Cervical Discectomy and Fusion (ACDF) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Encore Medical, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Metrics Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Encore Medical, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective parallel group comparison study to support expansion of the indication of the&#xD;
      company's FDA approved Spinalogicâ„¢ device to include the cervical spine. The SpinalogicTM&#xD;
      device was initially approved by FDA as an adjunct to one- or two-level lumbar fusion&#xD;
      (P910066/S011). It is a non-invasive bone growth stimulator (BGS) that generates a combined&#xD;
      magnetic field (CMF) that has been proven to accelerate bone healing and fusion in the lumbar&#xD;
      spine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to fusion</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the cervical fusion rate between treated and control group patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures VAS</measure>
    <time_frame>12 months</time_frame>
    <description>VAS Pain Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures NDI</measure>
    <time_frame>12 months</time_frame>
    <description>Neck Disability Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures OC</measure>
    <time_frame>12 months</time_frame>
    <description>Odum's Criteria</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Degeneration of Cervical Intervertebral Disc</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <description>Patients who underwent ACDF surgery and who received post surgical therapy with the SpinalogicTM Non-Invasive Bone Graft Stimulation Device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients who underwent ACDF surgery and did not receive post surgical Bone Graft Stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpinalogicTM Bone Graft Stimulator</intervention_name>
    <description>The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.</description>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects underwent primary anterior cervical discectomy and fusion (ACDF) and required two-&#xD;
        level cervical spine fusions. OR were active smokers and required either single or&#xD;
        two-level cervical spine fusions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or Female aged 18-75 years.&#xD;
&#xD;
          -  Primary anterior cervical discectomy fusion (ACDF) and required two level spinal&#xD;
             fusion or were active smokers and required either single or two level spinal fusion.&#xD;
&#xD;
          -  Pain VAS score &gt;5 and/or extreme weakness at target operative level(s).&#xD;
&#xD;
          -  At least one post operative clinical outcome assessment (VAS pain/ NDI/OC score) at&#xD;
             each follow up interval.&#xD;
&#xD;
          -  Completed 6 month follow up visit or time to fusion assessment, whichever is sooner.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Treated with a bone growth stimulator device other than the SpinalogicTM CMF device.&#xD;
&#xD;
          -  Previous cervical vertebrae fusion surgery at any level (posterior or anterior&#xD;
             approach)&#xD;
&#xD;
          -  Systemic administration of any type of corticosteroid, antineoplastic, immune-&#xD;
             stimulating or immunosuppressive agents within 30 days of primary ACDF surgery and/or&#xD;
             within 12 weeks post-operatively.&#xD;
&#xD;
          -  Active history of systemic malignancy at pre-operative assessment or during 12- month&#xD;
             follow up period.&#xD;
&#xD;
          -  Untreated malignant neoplasm(s) or underwent radiotherapy or chemotherapy at pre-&#xD;
             operative assessment or during 12-month follow up period.&#xD;
&#xD;
          -  Implanted with cardiac pacemaker or implantable cardioverter defibrillator at pre-&#xD;
             operative assessment or during 12-month follow up period.&#xD;
&#xD;
          -  Pregnant at pre-operative assessment or during 12-month follow up period.&#xD;
&#xD;
          -  Mental or physical condition that would interfere with post-treatment assessments&#xD;
             and/or care (e.g., neuromuscular disease, psychiatric disease,&#xD;
&#xD;
          -  Paraplegia, quadriplegia, etc.) at pre-operative assessment or during 12-month follow&#xD;
             up period.&#xD;
&#xD;
          -  Prescribed non-steroidal anti-inflammatory, calcium channel blockers and/or&#xD;
             diphosphonate therapy within 12-weeks of surgery period.&#xD;
&#xD;
          -  Prescribed bone morphogenic protein (BMP) during 12-month follow up period.&#xD;
&#xD;
          -  Implanted with a Titanium cage during the primary ACDF that precludes an outcome&#xD;
             determination via plain radiographs.&#xD;
&#xD;
          -  Osseous or ligamentous spinal trauma at pre-operative assessment or during 12- month&#xD;
             follow up period.&#xD;
&#xD;
          -  Paget's disease at pre-operative assessment or during 12-month follow up period.&#xD;
&#xD;
          -  Absence of X-ray fusion assessment documentation at 6 months follow-up visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruba Sarris, MPH</last_name>
    <role>Study Director</role>
    <affiliation>DJO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CLAIRE D WILLIAMS, MA</last_name>
    <phone>19789964243</phone>
    <email>Claire.Willams8@djoglobal.com</email>
  </overall_contact>
  <reference>
    <citation>Marquez-Lara A, Nandyala SV, Fineberg SJ, Singh K. Current trends in demographics, practice, and in-hospital outcomes in cervical spine surgery: a national database analysis between 2002 and 2011. Spine (Phila Pa 1976). 2014 Mar 15;39(6):476-81. doi: 10.1097/BRS.0000000000000165.</citation>
    <PMID>24365907</PMID>
  </reference>
  <reference>
    <citation>Eck JC, Hodges SD, Humphreys SC. Techniques for stimulating spinal fusion: efficacy of electricity, ultrasound, and biologic factors in achieving fusion. Am J Orthop (Belle Mead NJ). 2001 Jul;30(7):535-41. Review.</citation>
    <PMID>11482508</PMID>
  </reference>
  <reference>
    <citation>Gruskay JA, Webb ML, Grauer JN. Methods of evaluating lumbar and cervical fusion. Spine J. 2014 Mar 1;14(3):531-9. doi: 10.1016/j.spinee.2013.07.459. Epub 2013 Oct 31. Review.</citation>
    <PMID>24183750</PMID>
  </reference>
  <reference>
    <citation>Veeravagu A, Cole T, Jiang B, Ratliff JK. Revision rates and complication incidence in single- and multilevel anterior cervical discectomy and fusion procedures: an administrative database study. Spine J. 2014 Jul 1;14(7):1125-31. doi: 10.1016/j.spinee.2013.07.474. Epub 2013 Oct 11.</citation>
    <PMID>24126076</PMID>
  </reference>
  <reference>
    <citation>Leven D, Cho SK. Pseudarthrosis of the Cervical Spine: Risk Factors, Diagnosis and Management. Asian Spine J. 2016 Aug;10(4):776-86. doi: 10.4184/asj.2016.10.4.776. Epub 2016 Aug 16. Review.</citation>
    <PMID>27559462</PMID>
  </reference>
  <reference>
    <citation>Hilibrand AS, Fye MA, Emery SE, Palumbo MA, Bohlman HH. Impact of smoking on the outcome of anterior cervical arthrodesis with interbody or strut-grafting. J Bone Joint Surg Am. 2001 May;83(5):668-73.</citation>
    <PMID>11379735</PMID>
  </reference>
  <reference>
    <citation>Campbell PG, Yadla S, Nasser R, Malone J, Maltenfort MG, Ratliff JK. Patient comorbidity score predicting the incidence of perioperative complications: assessing the impact of comorbidities on complications in spine surgery. J Neurosurg Spine. 2012 Jan;16(1):37-43. doi: 10.3171/2011.9.SPINE11283. Epub 2011 Oct 28.</citation>
    <PMID>22035101</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

